New allergy shot shows promise in early trial

NCT ID NCT07052097

Completed Symptom relief Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested an injection called TQC2938, a humanized monoclonal antibody, in 136 adults with seasonal allergic rhinitis. All participants also used a standard nasal spray. The study measured how well the injection reduced nasal symptoms like sneezing and congestion over 2 and 4 weeks compared to a placebo. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQC2938 injection (a humanized monoclonal antibody)
What this could lead to: If it works, this could provide a new add-on treatment option for people with seasonal allergies who still have symptoms despite using standard nasal sprays.
What could go wrong: This is an early Phase 2 trial with only 136 participants, so results may not apply to everyone. The drug is still experimental and may not prove more effective than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEASONAL ALLERGIC RHINITIS

Contacts and locations

Locations

Affiliated Zhongshan Hospital Of Dalian university

Dalian, Liaoning, 116001, China
Baotou Central Hospital

Baotou, Inner Mongolia, 14000, China
Beijing TongRen Hospital, Capital Medical University

Beijing, Beijing Municipality, 100730, China
Cangzhou central hosipital

Cangzhou, Hebei, 061000, China
China-japan Friendship Hospital, Jilin University

Changchun, Jilin, 130033, China
First Affiliated Hospital, Heilongjang University of Chinese Medigine

Harbin, Heilongjang, 150040, China
First Hospital of Shangxi Medical University

Taiyuan, Shangxi, 30001, China
Ganzu Province People's Hospital

Lanzhou, Ganzu, 730000, China
General Hospital of Ningxia Medical University

Yinchuan, Ningxia, 750004, China
Hebei Medical University Third Hospital

Shijiazhuang, Hebei, 050000, China
Henan Provincial People's Hospital

Zhengzhou, Henan, 450002, China
Northern Jiangsu People'S Hospital

Yangzhou, Jiangsu, 225000, China
Peking University First Hospital

Beijing, Beijing Municipality, 100034, China
Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China
Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China
People'S Hospital of Zhengzhou

Zhengzhou, Henan, 450002, China
Qilu Hospital of Shandong University

Jinan, Shandong, 250021, China
Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710004, China
Shanxi Bethune Hospital

Taiyuan, Shanxi, 030000, China
Shengjing Hospital of China Medical University

Shenyang, Liaoning, 110004, China
The First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, 650032, China
The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine

Xi'an, Shaanxi, 710089, China
The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, 830013, China
The Second People's Hospital of Shandong Province

Jinan, Shandong, 250021, China
The first hospital of Jilin University

Changchun, Jilin, 130031, China
Tianjin First Central Hospital

Tianjin, Tianjin Municipality, 300192, China
Tongji Hospital of Tongji medical college of HUST

Wuhan, Hubei, 430030, China
Yantai Yuhuangding Hospital

Yantai, Shandong, 264000, China
Zhengzhou Central Hospital

Zhengzhou, Henan, 450007, China
Zibo Central Hospital

Zibo, Shandong, 255020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.